(CCUG)n RNA toxicity in a Drosophila model for myotonic dystrophy type 2 (DM2) activates apoptosis
Open Access
- 1 January 2017
- journal article
- research article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 10 (8) , 993-1003
Abstract
The myotonic dystrophies are prototypic toxic RNA gain-of-function diseases. Myotonic dystrophy type 1 (DM1) and type 2 (DM2) are caused by different unstable, noncoding microsatellite repeat expansions -- (CTG)DM1 in DMPK and (CCTG)DM2 in CNBP. Although transcription of mutant repeats into (CUG)DM1 or (CCUG)DM2 appears to be necessary and sufficient to cause disease, their pathomechanisms remain incompletely understood. To study the mechanisms of (CCUG)DM2 toxicity and develop a convenient model for drug screening, we generated a transgenic DM2 model in the fruit fly Drosophila melanogaster with (CCUG)n repeats of variable length (n=16 and 106). Expression of noncoding (CCUG)106, but not (CCTG)16, in muscle and retinal cells led to formation of (CCUG) ribonuclear inclusions and mis-splicing of genes implicated in the DM pathology. Mis-splicing could be rescued by co-expression of human MBNL1, while CUGBP1/CELF1 complementation did not. Flies with (CCUG)106displayed strong disruption of the external eye morphology and the underlying retina. Furthermore, expression of (CCUG)106 in developing retinae caused a strong apoptotic response. Inhibition of apoptosis rescued the retinal disruption in (CCUG)106 flies. Finally, we tested two chemical compounds that have shown therapeutic potential in DM1 models. While treatment of (CCUG)106 flies with pentamidine had no effect, treatment with a PKR inhibitor blocked both formation of RNA foci and apoptosis in retinae of (CCUG)106 flies. Our data indicate that expression of expanded (CCUG)DM2 repeats is toxic, causing inappropriate cell death in affected fly eyes. Our Drosophila DM2 model may provide a convenient tool for in vivo drug screening.Keywords
Funding Information
- National Institute of General Medical Sciences (GM068016)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (AR48171)
- Muscular Dystrophy Association (RG 4321)
- Kleberg Foundation
- National Cancer Institute (CA016672)
This publication has 77 references indexed in Scilit:
- Muscle weakness in myotonic dystrophy associated with misregulated splicing and altered gating of CaV1.1 calcium channelHuman Molecular Genetics, 2011
- RNA Foci, CUGBP1, and ZNF9 Are the Primary Targets of the Mutant CUG and CCUG Repeats Expanded in Myotonic Dystrophies Type 1 and Type 2The American Journal of Pathology, 2011
- In vivo discovery of a peptide that prevents CUG–RNA hairpin formation and reverses RNA toxicity in myotonic dystrophy modelsProceedings of the National Academy of Sciences, 2011
- Non-ATG–initiated translation directed by microsatellite expansionsProceedings of the National Academy of Sciences, 2010
- CUGBP1 overexpression in mouse skeletal muscle reproduces features of myotonic dystrophy type 1Human Molecular Genetics, 2010
- Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophyNature Structural & Molecular Biology, 2010
- Pentamidine reverses the splicing defects associated with myotonic dystrophyProceedings of the National Academy of Sciences, 2009
- A Z-DNA sequence reduces slipped-strand structure formation in the myotonic dystrophy type 2 (CCTG)·(CAGG) repeatProceedings of the National Academy of Sciences, 2009
- Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophyProceedings of the National Academy of Sciences, 2006
- Recruitment of human muscleblind proteins to (CUG)n expansions associated with myotonic dystrophyThe EMBO Journal, 2000